Semaglutide vs Tirzepatide: Which GLP-1 Is Better for Weight Loss?

If you're researching GLP-1 weight loss medications, you've almost certainly narrowed it down to two names: semaglutide and tirzepatide. These are the undisputed heavyweights of the category, and every online forum, doctor's office, and group chat seems to be debating which one is better. The honest answer? Both are remarkably effective. But they're not identical, and the differences matter — especially when it comes to how much weight you can expect to lose, the side effects you might experience, and what other health benefits come along for the ride. Let's break down the head-to-head comparison that everyone wants but few articles explain clearly.

The Tale of the Tape

Semaglutide — sold as Ozempic for diabetes and Wegovy for weight management — was the first GLP-1 receptor agonist to really capture public attention for weight loss. It's a once-weekly injection that mimics the GLP-1 hormone, helping you feel full faster, reducing appetite, and slowing how quickly your stomach empties. It was approved for weight management in 2021, and the clinical trial data has been nothing short of remarkable. Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight management — arrived on the scene a year later with an even more impressive trick up its sleeve. While semaglutide targets only the GLP-1 receptor, tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The theory is that hitting two incretin pathways simultaneously amplifies the metabolic effects.¹

Weight Loss: The Numbers Everyone Cares About

Let's start with the headline number, because that's what most people want to know: how much weight can I actually lose? In the landmark STEP 1 trial, semaglutide 2.4 mg produced an average weight loss of about 15% of body weight over 68 weeks. About one-third of participants lost 20% or more. The placebo group, by comparison, lost about 2.4%.² Those numbers were considered groundbreaking at the time — no previous anti-obesity medication had come close to matching what bariatric surgery could achieve. Then tirzepatide entered the conversation. In the SURMOUNT-1 trial, the highest dose (15 mg) produced an average weight loss of about 20.9% over 72 weeks. Roughly half of participants on the highest dose lost 20% or more of their body weight. Some individuals in the trial lost over 25%.¹ By the raw numbers, tirzepatide wins the weight loss contest. The difference — approximately 6 percentage points of additional weight loss on average — is clinically meaningful. That's the equivalent of an additional 12 to 15 pounds for someone starting at 200 pounds. But there's important context here. The STEP and SURMOUNT trials used different study populations, slightly different protocols, and different endpoints. You can't directly compare results across trials the way you'd compare results from a head-to-head study. It's like comparing two athletes' personal bests from different competitions on different days — suggestive, but not definitive. The good news? A direct head-to-head trial called SURMOUNT-5 has been comparing tirzepatide and semaglutide in the same study population. Early results confirm that tirzepatide produces greater weight loss, but the gap may be somewhat smaller than cross-trial comparisons would suggest.³ Both medications are highly effective; tirzepatide just edges ahead.

How They Work: Single vs Dual Action

The fundamental difference between these two drugs comes down to their mechanism. Semaglutide is a pure GLP-1 receptor agonist. It mimics one incretin hormone — GLP-1 — and does so very effectively. GLP-1 slows gastric emptying, stimulates insulin secretion, suppresses glucagon, and signals satiety in the brain. It's a well-proven mechanism with a deep body of evidence behind it.⁴ Tirzepatide adds GIP receptor activation on top of the GLP-1 effects. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that works alongside GLP-1. The combination appears to enhance weight loss beyond what GLP-1 alone can achieve, possibly through additional effects on fat metabolism and insulin sensitivity.¹ Whether the GIP component truly adds meaningful benefit, or whether tirzepatide's superior weight loss is due to other factors (like its specific receptor binding profile), is still a matter of scientific debate. What we know for certain is that in clinical trials, the dual-agonist approach has produced greater weight loss than the single-agonist approach.

The Cardiovascular Question

This is where the comparison gets really interesting — and where semaglutide currently holds a significant advantage. The SELECT trial enrolled over 17,600 people with obesity or overweight and established cardiovascular disease (but without diabetes) and randomized them to semaglutide 2.4 mg or placebo. The results were striking: semaglutide reduced the risk of major adverse cardiovascular events — heart attack, stroke, or death from cardiovascular causes — by 20% over an average of about 3 years.⁵ This is the first time any weight loss medication has demonstrated hard cardiovascular outcomes in people with obesity, even without diabetes. It's not just about losing weight anymore — semaglutide appears to be directly protecting the heart and blood vessels. Tirzepatide's cardiovascular story is still being written. The SURPASS-CVOT trial compared tirzepatide to dulaglutide in people with type 2 diabetes and showed that tirzepatide was non-inferior for major cardiovascular events. However, a dedicated trial in people with obesity (without diabetes), similar to SELECT, is ongoing and hasn't reported results yet. If you have existing cardiovascular disease — a prior heart attack, stent placement, stroke, or established atherosclerotic disease — the cardiovascular protection data for semaglutide is a major point in its favor. That 20% reduction in MACE isn't a theoretical benefit; it's a demonstrated, real-world reduction in life-threatening events.

Side Effects: More Alike Than Different

When it comes to side effects, semaglutide and tirzepatide are more similar than different. Both medications cause gastrointestinal side effects as their primary adverse events: nausea, vomiting, diarrhea, and constipation are the most common complaints with both drugs.¹² The intensity of GI side effects generally correlates with the potency of weight loss — the more weight a medication helps you lose, the more GI discomfort you're likely to experience during the dose escalation period. In cross-trial comparisons, the rates of GI side effects are broadly similar between the two drugs at comparable stages of treatment. Both medications require slow dose escalation to minimize side effects. Semaglutide is typically titrated from 0.25 mg to the full 2.4 mg dose over about 16 to 20 weeks. Tirzepatide follows a similar escalation pattern, starting at 2.5 mg and working up to 15 mg over several months. One practical note: some people who experience intolerable side effects on one medication find that they tolerate the other better, or vice versa. If semaglutide gives you persistent nausea that doesn't improve, switching to tirzepatide (or the reverse) is a reasonable strategy to discuss with your provider. The medications are similar but not identical in their side effect profiles at the individual level.

Cost and Access: The Practical Reality

Let's talk about what many comparison articles gloss over: money. These medications are expensive, and insurance coverage varies wildly. As of the most recent pricing data, tirzepatide (Zepbound) has a slightly lower list price than semaglutide (Wegovy) — typically around $1,060 per month versus approximately $1,350 per month. However, what you actually pay depends almost entirely on your insurance coverage, any manufacturer savings programs you qualify for, and whether your plan covers weight loss medications at all. Many insurance plans have been slow to cover GLP-1 medications for weight loss, though this is gradually improving as more data demonstrates the health benefits beyond the scale. The cardiovascular protection data for semaglutide may help with insurance coverage, as payers are more likely to cover medications that reduce expensive health events like heart attacks and strokes. Both medications also have availability from compounding pharmacies, which can offer lower-cost alternatives, though the quality and regulation of compounded versions varies. If cost is a major deciding factor for you, this conversation with your insurance company and your provider is just as important as the clinical comparison. The best medication in the world isn't helpful if you can't afford to take it consistently.

Who Should Choose Semaglutide?

Semaglutide might be the better choice if:

• You have existing cardiovascular disease and want the proven heart protection from the SELECT trial data
• Your insurance covers Wegovy but not Zepbound
• You value having the most extensively studied GLP-1 medication with the largest body of long-term data
• You're doing well on semaglutide already and see no reason to switch
• You've tried tirzepatide and didn't tolerate it well

Who Should Choose Tirzepatide?

Tirzepatide might be the better choice if:

• Maximum weight loss is your primary goal and you want the medication with the highest average weight loss in clinical trials
• You've plateaued on semaglutide and want to try a different mechanism
• Cost is a significant factor and tirzepatide's lower list price makes a difference for your situation
• You have type 2 diabetes and want the additional insulin sensitivity benefits of dual GIP/GLP-1 agonism
• You're comfortable with a newer medication that has somewhat less long-term data

The Bigger Picture

Here's what often gets lost in the semaglutide-versus-tirzepatide debate: both of these medications are transformative compared to what was available even five years ago. Before GLP-1 medications, the best anti-obesity drugs produced average weight losses of about 5 to 10%. Now we're talking about 15 to 21%. That's a fundamentally different category of treatment. The choice between semaglutide and tirzepatide is a choice between "very good" and "slightly better" — not between "good" and "bad." Whichever one you and your provider choose, you're accessing a medication that would have been considered impossible just a decade ago. Both medications work best as part of a comprehensive approach that includes dietary changes, regular exercise (especially resistance training to preserve muscle mass), behavioral support, and ongoing medical supervision. The medication is a powerful tool, but it's one tool in a larger toolkit. And remember: this is a rapidly evolving field. New data is emerging constantly, new medications are in development (including oral formulations and triple agonists), and the comparison landscape will continue to shift. The "best" medication today may not be the best medication in two years. What matters is starting with a good option, monitoring your results, and being willing to adjust your approach as new evidence and options become available.

References

[1] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed [2] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed [3] Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026. PubMed [4] Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PubMed [5] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed

Always discuss medication choices with your healthcare provider. This article is for informational purposes only and is not a substitute for personalized medical advice.